Filing Flows › Aktis Oncology (AKTS) › Next earnings date
Aktis Oncology (AKTS) earnings on Nov 12, 2026: what to expect
Aktis Oncology (AKTS) is expected to report earnings on Nov 12, 2026 (estimated), in 4 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.45 (−$0.56 to −$0.34, 7 estimates) on revenue of $2.5M. It beat the EPS estimate in 0% of the quarters on record; Filing Flows' model gives it a 51% chance of beating next time.
What to watch
Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:
The last report
Aktis Oncology reported revenue of $3.4M for the second quarter 2026 (+111% Y/Y), net loss $24.1M. How it makes money → · Every quarter →
Aktis Oncology's latest quarter
Aktis Oncology, Q2 2026: revenue $3.4M (+111% year over year), operating margin -854.0%, net loss $24.1M, operating cash flow −$20.6M. The chart follows the revenue to costs, profit and cash.
Questions
When does AKTS report earnings?
Aktis Oncology is expected to report on Nov 12, 2026 (estimated).
What are analysts expecting from Aktis Oncology?
EPS of −$0.45 and revenue of $2.5M for the quarter.
Does Aktis Oncology usually beat earnings?
It beat the consensus EPS estimate in 0% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.